Glaucoma is the major cause of irreversible blindness throughout the world. Of all of the treatments that are available at present, the most effective appears to be surgery; however, excessive conjunctival scarring can lead to surgical failure. In the last decade, the introduction of the anti-metabolites mitomycin-C and 5-fluorouracil as anti-scarring treatments have greatly improved the results of glaucoma surgery, but these agents are associated with complications that can potentially result in blindness. A possible target for a more physiological approach to anti-scarring is transforming growth factor β. This review examines the role of transforming growth factor β in conjunctival scarring and discusses promising new ways of modifying its activity.
Skip Nav Destination
Review Article| January 17 2003
Role of transforming growth factor β in conjunctival scarring
M. Francesca CORDEIRO
1Department of Pathology, Moorfields Eye Hospital and Institute of Ophthalmology, Bath Street, London EC1V 9EL, U.K., and Department of Glaucoma, Moorfields Eye Hospital and Institute of Ophthalmology, Bath Street, London EC1V 9EL, U.K.
Correspondence: Dr Francesca Cordeiro (e-mail firstname.lastname@example.org).
Search for other works by this author on:
Clin Sci (Lond) (2003) 104 (2): 181–187.
- Views Icon Views
- Share Icon Share
M. Francesca CORDEIRO; Role of transforming growth factor β in conjunctival scarring. Clin Sci (Lond) 1 February 2003; 104 (2): 181–187. doi: https://doi.org/10.1042/cs1040181
Download citation file:
Don't already have an account? Register
Get Access To This Article
Buy This Article